Anusha Kalbasi

🚨What if we could reliably program macrophage polarization state?🚨 biorxiv.org/content/10.648… Macrophages are highly plastic immune cells that perform critical functions by polarizing into distinct cellular states. The polarization state of macrophages can substantially influences the progression of cancers, infections, and autoimmunity. (1/11)

If you haven’t REAP’d, have you really lived?

@CampKatiee @ToniRibas12 @parkerici @SWOG @SU2C @Agilent @Covaris @AACR @UCLAJCCC congrats @CampKatiee, Toni, and team!

Incredibly proud to share this work with @ToniRibas12 Thank you to all collaborators and support @parkerici @SWOG @SU2C @Agilent @Covaris @AACR @UCLAJCCC

Made possible by Marisol Quintero & team @Highlight_HLT, @theNCI, @StanfordCancer, @ConquerCancerFd, @UCLAJCCC. And most importantly, our patients. /10

Congrats to first author @JieDeng (my first post-doc, now leading her own group), UCLA Sarcoma program, and our @StanfordMed team on rich correlatives (@AasthaPal @Stef_Tst @ZinaGood @aaronmring @everettmoding) /9

Radiation is a powerful anti-cancer agent, but I considered it a weak immunomodulator. Our new study @CD_AACR changed my mind: in the right context, RT can incite potent systemic immune responses in patients (even rare irAEs). Which context? brnw.ch/21x1b6E A 🧵 /1

@QinliSun @ScienceKyle @Nature Congrats Qinli!

Excited to share our new @Nature paper! We developed an IL-2–TGFβ co-agonist that enables efficient induction of antigen-specific pTregs and establishment of immune tolerance in vivo. An important step toward programmable immune tolerance. rdcu.be/e72lN

Thrilled to share the primary focus of my PhD thesis work, now out in @ScienceMagazine today! We developed Trikines — engineered cytokines that reconfigure receptor complex assembly to reshape signaling directly in endogenous immune cells. doi.org/10.1126/scienc…

@SprakerMDPhD @EvanThomas84 Take a look at details on fractures in manuscript. Some clearly not RT related and w so few fx cases hard to conclude on dosimetry, but with our Stanford study reporting soon hopefully across 2 studies we will reveal any dose parameters. SWOG RCT forthcoming from Jeremy Harris

@EvanThomas84 I agree on the fractures, would be nice to see the dosi. Otherwise, this is a reasonable toxicity profile for a relatively high risk cohort (smokers, some diabetics, 70% lower extremity). Not sure I agree we need an RCT. Pooled analysis of prospective patients would be cool.

Interesting study- they mention patients undergoing electron therapy though….. Which means those would NOT be SBRT treatments. I’d be surprised if wound complication rates were NOT worse in patients receiving electrons. I would love to see treatment planning data from this study. @rickysavjani can you fill us in?

@EvanThomas84 this is an update on our original report of early outcomes data from 50 pts at UCLA pubmed.ncbi.nlm.nih.gov/32054730/ Only 1 or 2 pts if I recall in total were treated with electrons. Vast majority IMRT, a handful 3DCRT. We didn’t call it SBRT, though it is a bit of semantics here.

thanks @JoeFraietta and Janna for having me on!

Two complementary studies from our group out today: a therapeutic peptide vaccine trial for fibrolamellar carcinoma (FLC) & TIRTL-Seq, our robust method for deep quantitative paired TCR sequencing a🧵w/ @MarkYarchoan & @pogorely nature.com/articles/s4159… & nature.com/articles/s4159…

IL-9 enhancement of engineered CAR-T therapies @ImmunityCP @carlhjune @msofiacastelli @Penn @xrtcell @stanford @KaylaKulhanek cell.com/immunity/fullt… cell.com/immunity/fullt…